UPDATED: Kite Pharma soars on added evidence that CAR-T treatment quells cancer

John Carroll Kite Pharma has once again demonstrated just how hot experimental CAR-T technology is in the cancer field. The Santa Monica, CA-based biotech reported Monday evening in ...

UPDATED: Amgen axing up to 2,900 staffers, shuttering sites in major restructuring

John Carroll Bracing for an expensive round of late-stage studies and potential drug launches as it ramps up work on a slate of new biosimilars, Amgen reported Tuesday evening that ...

UPDATED: Targacept’s litany of trial failures continues with yet another flop

John Carroll On Monday, Targacept reported that its midstage effort aimed at salvaging its lead drug flopped. Once partnered with AstraZeneca, which saw four late-stage studies for ...

UPDATED: Gilead picks up blockbuster FDA blood cancer approvals for idelalisib

John Carroll Gilead said today that the FDA has approved its PI3k inhibitor idelalisib for three types of B-cell blood cancers following its early Phase III success last fall on impressive ...

UPDATED: FDA gives an early OK to lymphoma drug Beleodaq

John Carroll Spectrum Pharmaceuticals has won an early nod from the FDA for belinostat, a new T-cell lymphoma drug that will be sold as Beleodaq. FierceBiotech News

UPDATED: FDA experts spurn AstraZeneca’s pitch for ovarian cancer drug olaparib

John Carroll AstraZeneca's top investigators took their best case for an accelerated approval of the failed cancer drug olaparib to the FDA's panel of outside experts on Wednesday, ...

UPDATED: Pfizer hikes bid for AstraZeneca to $117B, swears off hostile maneuver

John Carroll Pfizer has upped its bid for AstraZeneca to £55 a share, or $ 117 billion, hitting the "magic number" that bankers close to these talks ...

UPDATED: Ex-champ Vertex dumps hep C, but shares spike on positive CF results

John Carroll With Gilead's Sovaldi elbowing Vertex's Incivek aside, Vertex is calling it quits on a once-ambitious R&D effort to keep a niche for itself in hepatitis C. ...

UPDATED: FDA panel says Aleve should keep its heart-risk warning

Eric Palmer Bayer's painkiller Aleve carries the same heart-risk warning as other nonsteroidal anti-inflammatories, or NSAIDs, like Motrin and Advil. And as far as an FDA review ...

UPDATED: FDA OKs AstraZeneca’s long-delayed diabetes drug dapagliflozin

John Carroll The FDA has handed AstraZeneca a green light to begin marketing dapagliflozin, its long-delayed SGLT2 diabetes drug, which will now try to defy ...

UPDATED: FDA casts ‘fatal’ doubts on Sanofi’s long-stalled MS drug Lemtrada

Damian Garde Sanofi's multiple sclerosis drug Lemtrada may be too dangerous to warrant FDA approval, agency staff said, potentially damning news for an injection that has slogged ...

UPDATED: The ax drops at troubled Merck as big restructuring gets underway

John Carroll The pink slips are starting to fly at Merck R&D. The rumor mill was running full tilt on Monday morning, with comments flowing across Twitter that planned layoffs are ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS